← Back to Search

Cancer Vaccine

Candin vaccine for Oral Squamous Cell Carcinoma

Phase 2
Recruiting
Led By Omar Atiq
Research Sponsored by University of Arkansas
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No Evidence of Disease (NED) based on clinical and/or radiographic evaluations
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, up to 2 years
Awards & highlights

Study Summary

This trial will test the effectiveness and safety of Candin in reducing cancer recurrence rates over two years. Participants will either receive Candin or a placebo, with more participants receiving Candin. Up to

Who is the study for?
This trial is for adults over 18 with squamous cell carcinoma of the head and neck who've finished curative therapy within the last 120 days and currently show no signs of disease. Participants must be able to follow study procedures and give informed consent.Check my eligibility
What is being tested?
The study tests a vaccine called Candin, given in seven doses over two years, against a saline placebo to see if it can lower cancer recurrence rates. For every three participants receiving Candin, one will get the placebo.See study design
What are the potential side effects?
Potential side effects are not detailed here but may include reactions at the injection site or immune responses due to vaccination.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My tests show no signs of cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Assessment of clinical efficacy
Secondary outcome measures
Assessment of adverse events

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Candin vaccineActive Control1 Intervention
Seven Candida (Candin). The route of administration is intradermal injection at subject's limbs at 0.5 mL/injection. The schedule is 1 injection every three weeks for the first 4 injections, and then one injection every 3 months until a total of 7 injections has been given.
Group II: PlaceboPlacebo Group1 Intervention
Seven placebo injections (sterile 0.9% Normal Saline). The route of administration is intradermal injection at subject's limbs at 0.5 mL/injection. The schedule is 1 injection every three weeks for the first 4 injections, and then one injection every 3 months until a total of 7 injections has been given.

Find a Location

Who is running the clinical trial?

University of ArkansasLead Sponsor
486 Previous Clinical Trials
150,253 Total Patients Enrolled
Omar AtiqPrincipal InvestigatorUniversity of Arkansas

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are new participants currently being enrolled in this ongoing medical study?

"According to clinicaltrials.gov, this investigation is presently not seeking participants. The trial was initially listed on February 1st, 2024 and underwent its latest revision on February 7th, 2024. However, amidst the current non-recruitment status of this study, it's worth noting that there are a total of 1731 other ongoing trials actively enrolling patients at present."

Answered by AI

What is the level of safety associated with the Candin vaccine in individuals?

"Based on our analysis at Power, the safety rating for the Candin vaccine is 2. This assessment aligns with the Phase 2 trial nature where some safety data exists but efficacy remains unproven."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
2024. "Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05952934.
All > Hnscc > Head And Neck Cancer
~67 spots leftby Feb 2029
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top